Laurence Gilles-Afchain

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

Anne‐Laure Giraudet, Philippe A. Cassier, Chicaco Iwao-Fukukawa et al. · BMC Cancer · 2018 · 65 citations · Full text

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Philippe A. Cassier, Gwenaëlle Garin, Lauriane Eberst et al. · Journal of Clinical Oncology · 2019 · 45 citations

Fixed Dose, Immunology, Pathology +21

The PhaSeal® system: Impact of its use on workplace contamination and duration of chemotherapy preparation

Bertrand Favier, H Labrosse, Laurence Gilles-Afchain et al. · Journal of Oncology Pharmacy Practice · 2011 · 41 citations

A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors

Philippe A. Cassier, Lauriane Eberst, G. Garin et al. · Annals of Oncology · 2019 · 17 citations

External contamination of antineoplastic drug vials: an occupational risk to consider

Camille Cotteret, Philippe-Henri Secrétan, Laurence Gilles-Afchain et al. · European Journal of Hospital Pharmacy · 2020 · 15 citations · Full text

Food Packaging, Exposure Assessment, Dermatology +21